explore -WSS

explore

author：knowledge 2025-09-14 21:37:38 - browse：6665

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Ukraine seeks to reclaim its role as a hub for clinical trials

knowledge

WSS

A new drug could help frostbite victims avoid its ravages

A new drug could help frostbite victims avoid its ravages

Surprise medical billing ban raises prices elsewhere

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Trump Jan. 6 attorney John Lauro is ex

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Jerome Adams on the need for new antivirals for Covid

Measles policy set amid Florida outbreak alarms vaccine proponents

Bright Health sells Medicare Advantage business to Molina

Hospitals are piloting generative AI tools as regulators play catch

Duchenne breakthrough therapy leaves behind pioneering families

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Novavax promises a turnaround & Lilly roils the obesity market

In 'major milestone,' FDA approves first cell therapy for solid tumors

hotspot

Surprise medical billing ban raises prices elsewhere

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Moderna hits safety problems in bold bid to reinvent medicine

Flagship Pioneering startup Sonata Therapeutics lays off 21

Congress may force more Covid

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

explore

knowledge

knowledge

leisure time